Eli Lilly increases investment in "weight loss drug": announces $5.3 billion investment to expand production capacity

According to media reports on Friday, Eli Lilly and Company has made a major decision to invest $5.3 billion to increase the production capacity of tirzepatide, a key ingredient in its weight loss and diabetes injection drugs.

This investment not only adds to existing plans but is also the largest investment in the company's nearly 150-year history.

This will expand its production facilities in Indiana, which produce the active ingredients of the weight loss drug Zepbound and the diabetes blockbuster drug Mounjaro, tirzepatide.

Stay tuned for more updates